

Consolidated Financial Statements

August 31, 2022 and 2021

(With Independent Auditors' Report Thereon)



KPMG LLP Suite 2000 303 Peachtree Street, N.E. Atlanta, GA 30308-3210

Independent Auditors' Report

The Board of Trustees The Carter Center, Inc.

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the consolidated financial statements of The Carter Center, Inc. and its subsidiary (the Center), which comprise the consolidated statements of financial position as of August 31, 2022 and 2021, and the related consolidated statements of activities, functional expenses, and cash flows for the years then ended, and the related notes to the consolidated financial statements.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Center as of August 31, 2022 and 2021, and the changes in its net assets and its cash flows for the years then ended in accordance with U.S. generally accepted accounting principles.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the Center and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with U.S. generally accepted accounting principles, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Center's ability to continue as a going concern for one year after the date the consolidated financial statements are available to be issued.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are



considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with GAAS and Government Auditing Standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are
 appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of
 the Center's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting
 estimates made by management, as well as evaluate the overall presentation of the consolidated financial
 statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Center's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated May 5, 2023 on our consideration of the Center's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Center's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Center's internal control over financial reporting and compliance.



Atlanta, Georgia May 5, 2023

Consolidated Statements of Financial Position

August 31, 2022 and 2021

Assets	2022	2021
Cash and cash equivalents	\$ 75,452,534	66,284,099
Accounts receivable: Due from conditional agreements Other	8,787,185 272,740	5,891,939 324,728
Total accounts receivable	9,059,925	6,216,667
Contributions receivable, net (note 3) Inventory (notes 4, 9, and 15) Investments (notes 5 and 7) Property, plant, and equipment, net (note 6) Artwork Other assets	230,163 4,387,783 1,058,873,553 4,923,280 2,435,365 33,286	287,519 761,043 1,178,629,329 4,467,709 2,435,365 214,191
Total assets	\$ 1,155,395,889	1,259,295,922
Liabilities and Net Assets		
Liabilities: Accounts payable and accrued expenses Deferred revenue Annuity obligations (note 7)	\$ 9,932,820 6,111,603 6,204,467	8,044,561 4,790,884 5,624,221
Total liabilities	22,248,890	18,459,666
Net assets (note 11): Without donor restrictions With donor restrictions Total net assets	423,491,324 709,655,675 1,133,146,999	454,689,287 786,146,969 1,240,836,256
Commitments and contingencies (notes 7, 8, and 16)		.,240,000,200
Total liabilities and net assets	\$ 1,155,395,889	1,259,295,922

See accompanying notes to consolidated financial statements.

Consolidated Statement of Activities

Year ended August 31, 2022 (with comparative totals for 2021)

		Without donor With donor		Tot	otals	
		restrictions	restrictions	2022	2021	
Revenue and support:						
Contributions and grants:						
Operating	\$	44,139,241	_	44,139,241	37,827,527	
Programs:						
Health		_	39,935,489	39,935,489	35,573,733	
Peace		_	10,635,582	10,635,582	13,873,866	
Cross-program		_	192,618	192,618	328,810	
In-kind gifts (note 9):						
Health		—	193,676,160	193,676,160	204,335,299	
Peace		_	_	_	115,000	
Endowment			309,185	309,185	32,593	
Total contributions and						
grants		44,139,241	244,749,034	288,888,275	292,086,828	
Endowment fund earnings Appreciation of		13,180,421	23,230,237	36,410,658	35,076,995	
endowment investments, net		(44,187,191)	(75,817,149)	(120,004,340)	300,798,458	
Facilities use income		252,509	_	252,509	115,397	
Interest and investment income		31,566	—	31,566	6,108	
Net assets released from restrictions:						
Health		251,788,694	(251,788,694)	—	—	
Peace		16,190,835	(16,190,835)	_	—	
Cross-program		673,887	(673,887)			
Total revenue and						
support		282,069,962	(76,491,294)	205,578,668	628,083,786	
Expenses: Program:						
Health		261,125,289		261,125,289	270,061,266	
Peace		26,900,511		26,900,511	23,272,069	
Cross-program		1,843,904	_	1,843,904	571,419	
Fundraising		11,610,169	_	11,610,169	9,955,592	
General and administrative		11,788,052	_	11,788,052	10,776,042	
Total expenses	•	313,267,925		313,267,925	314,636,388	
Change in net assets		(31,197,963)	(76,491,294)	(107,689,257)	313,447,398	
Net assets at beginning of year		454,689,287	786,146,969	1,240,836,256	927,388,858	
Net assets at end of year	\$	423,491,324	709,655,675	1,133,146,999	1,240,836,256	

See accompanying notes to consolidated financial statements.

Consolidated Statement of Activities

Year ended August 31, 2021

	Without donor restrictions	With donor restrictions	Total
Revenue and support:			
Contributions and grants:			
Operating	\$ 37,827,527	_	37,827,527
Programs:			
Health	_	35,573,733	35,573,733
Peace	—	13,873,866	13,873,866
Cross-program	—	328,810	328,810
In-kind gifts (note 9):			
Health	—	204,335,299	204,335,299
Peace	—	115,000	115,000
Endowment		32,593	32,593
Total contributions and			
grants	37,827,527	254,259,301	292,086,828
Endowment fund earnings Appreciation of	12,698,652	22,378,343	35,076,995
endowment investments, net	107,685,518	193,112,940	300,798,458
Facilities use income	115,397	· · · —	115,397
Interest and investment income	2,546	3,562	6,108
Net assets released from restrictions:			
Health	260,593,340	(260,593,340)	—
Peace	14,842,941	(14,842,941)	_
Cross-program	397,639	(397,639)	
Total revenue and			
support	434,163,560	193,920,226	628,083,786
Expenses:			
Program:			
Health	270,061,266		270,061,266
Peace	23,272,069		23,272,069
Cross-program	571,419	_	571,419
Fundraising	9,955,592	_	9,955,592
General and administrative	10,776,042	_	10,776,042
Total expenses	314,636,388		314,636,388

Consolidated Statement of Functional Expenses

Year ended August 31, 2022 (With comparative totals for 2021)

	Р	rogram expenses	5	Supportin	g expenses		
			Cross-		General and	Тс	otal
	Health	Peace	program	Fundraising	administrative	2022	2021
Salaries and benefits	\$ 25,163,228	12,271,525	226,777	4,757,418	6,109,799	48,528,747	45,193,400
Consulting	7,431,564	5,096,448	429,708	422,726	2,017,790	15,398,236	13,577,699
Communications	2,863,071	898,857	4,550	2,549,798	232,575	6,548,851	5,958,285
Services	252,997	807,028	2,508	1,822,813	487,319	3,372,665	2,546,986
Office and equipment	3,046,108	1,166,654	34,097	168,671	729,754	5,145,284	4,177,205
Vehicles	3,918,949	458,738	22	368	609	4,378,686	4,986,767
Travel/meetings	16,677,506	2,630,142	9,106	1,034,685	141,797	20,493,236	16,807,030
Interventions (note 2(k))	197,241,072	_	—	—	—	197,241,072	211,817,490
Other	1,321,847	406,321	3,753	377,025	1,279,834	3,388,780	2,789,089
Grants	2,657,408	2,760,638	1,105,470			6,523,516	4,654,189
	260,573,750	26,496,351	1,815,991	11,133,504	10,999,477	311,019,073	312,508,140
Common area and depreciation	551,539	404,160	27,913	476,665	788,575	2,248,852	2,128,248
Total expenses	\$	26,900,511	1,843,904	11,610,169	11,788,052	313,267,925	314,636,388

See accompanying notes to consolidated financial statements.

Consolidated Statement of Functional Expenses

Year ended August 31, 2021

	F	Program expenses			Program expenses Supporting expenses			
	Health	Peace	Cross- program	Fundraising	General and administrative	Total		
Salaries and benefits	\$ 23,341,825	10,666,365	220,349	4,887,534	6,077,327	45,193,400		
Consulting	6,324,601	5,086,580	58,557	594,339	1,513,622	13,577,699		
Communications	2,865,186	596,455	3,177	2,281,917	211,550	5,958,285		
Services	205,835	629,028	7,607	1,210,247	494,269	2,546,986		
Office and equipment	2,530,663	924,705	2,157	177,767	541,913	4,177,205		
Vehicles	4,654,024	331,942	17	295	489	4,986,767		
Travel/meetings	15,133,744	1,611,528	98	39,872	21,788	16,807,030		
Interventions (note 2(k))	211,817,490	_	—	—	—	211,817,490		
Other	1,154,082	150,648	3,041	312,519	1,168,799	2,789,089		
Grants	1,511,856	2,892,333	250,000			4,654,189		
	269,539,306	22,889,584	545,003	9,504,490	10,029,757	312,508,140		
Common area and depreciation	521,960	382,485	26,416	451,102	746,285	2,128,248		
Total expenses	\$_270,061,266	23,272,069	571,419	9,955,592	10,776,042	314,636,388		

Consolidated Statements of Cash Flows

Years ended August 31, 2022 and 2021

	-	2022	2021
Cash flows from operating activities:			
Change in net assets	\$	(107,689,257)	313,447,398
Adjustments to reconcile change in net assets to net cash			
provided by operating activities:			
Depreciation		755,972	666,632
Appreciation of endowment investments, net		120,004,340	(300,711,231)
Appreciation of non-endowment investments, net		(32,866)	(87,227)
Donated artwork		(000 405)	(6,750)
Contributions restricted in perpetuity, net		(309,185)	(84,494)
Net change in inventory balances due to noncash contributions and distributions		(2, 626, 740)	4 400 000
Changes in operating assets and liabilities:		(3,626,740)	1,488,323
Accounts receivable		(2,843,258)	2,432,912
Contributions receivable, net of donor endowment		57,356	1,362,500
Other assets		180,905	105,854
Accounts payable and accrued expenses, deferred		,	,
revenue, and annuity obligations	-	4,760,920	(638,305)
Net cash provided by operating activities	-	11,258,187	17,975,612
Cash flows from investing activities:			
Purchase of property and equipment, net of related payables		(1,138,794)	(915,832)
Endowment fund earnings		(36,410,658)	(35,076,995)
Purchase of investments		(1,488,025)	(1,706,978)
Sale of investments	-	37,402,972	35,426,896
Net cash used in investing activities	-	(1,634,505)	(2,272,909)
Cash flows from financing activities:			
Contributions restricted in perpetuity, net		309,185	84,494
Payments on annuities and trusts		(764,432)	(734,295)
Net cash used in financing activities	-	(455,247)	(649,801)
Net change in cash and cash equivalents	-	9,168,435	15,052,902
Cash and cash equivalents at beginning of year		66,284,099	51,231,197
Cash and cash equivalents at end of year	\$	75,452,534	66,284,099
Cash and Cash equivalents at end of year	Ψ	70,402,004	00,204,033
Supplemental disclosures for cash flow information: Noncash investing activity – purchases of property and equipment in accounts payable	\$	72,749	_

See accompanying notes to consolidated financial statements.

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

(1) Organization and Operation

The Carter Center, Inc. (the Center), formerly known as Carter Presidential Library, Inc. and Carter Presidential Center, Inc., was organized on October 26, 1981 under the laws of the State of Georgia as a not-for-profit corporation to be operated exclusively for charitable and educational purposes.

The Center operates programmatically under two main action areas: Peace and Health. The Center also receives broad-based support deemed to be beneficial to all programs and categorized as Cross-program.

Initiatives in Peace include preventing and resolving conflict, protecting basic human rights, promoting rule of law, and monitoring elections in emerging democracies. The Health area strives to improve health in the United States and around the world. Initiatives include disease eradication and control and mental health reform. The Center operates field offices in various African, Asian, and Latin American countries, as needed, to fulfill its programmatic objectives.

The board of trustees (the Board) of the Center consists of President Carter and Mrs. Carter, the president of Emory University, 10 members appointed by Emory University's board of trustees, and 11 members appointed by President Carter and those trustees not appointed by Emory University's board of trustees (Carter Center class of the Center's trustees). Additionally, Emory University's board of trustees has the authority to approve amendments to the Center's articles of incorporation and bylaws. Carter Center of Emory University (CCEU) (an affiliate of CCI) is a department of Emory University that was established to assist with the operations of the Center's programs. The financial data for CCEU is not included in these consolidated financial statements as it is considered part of the Emory University reporting entity.

(2) Summary of Significant Accounting Policies and Other Matters

(a) Basis of Accounting

The consolidated financial statements of the Center have been prepared on the accrual basis of accounting in conformity with U.S. generally accepted accounting principles.

(b) Principles of Consolidation

The consolidated financial statements of the Center include the activity of The Carter Center Collaborative, Inc. (CCCI), an affiliated tax-exempt not-for-profit corporation that supports the Center's mission through receipt of in-kind goods and services. All significant intercompany transactions are eliminated on consolidation.

(c) Basis of Presentation

Net assets and revenue, expenses, gains, and losses are classified based on the existence or absence of donor-imposed restrictions. Accordingly, net assets of the Center and changes therein are classified and reported as follows:

Net assets without donor restrictions – Net assets that are not subject to donor-imposed stipulations.

Net assets with donor restrictions – Net assets subject to donor-imposed stipulations that may or will be met either by actions of the Center and/or the passage of time.

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

(d) Cash and Cash Equivalents

The Center's cash and cash equivalents represent liquid financial instruments with an original maturity of three months or less that are not invested as part of the investment assets. These amounts, carried at cost, approximate fair value.

(e) Contributions

Contributions received are recognized as revenue when underlying assets or a donor's unconditional promise to give is received. Contributions are considered to be available for use without restriction unless specifically restricted by the donor. Amounts received that are designated for future periods or restricted by the donor for specific purposes are reported as support that increases net assets with donor restrictions.

Unconditional promises to give that are expected to be collected within one year are recorded at net realizable value. Unconditional promises to give that are expected to be collected in future years are recorded at the present value of their estimated future cash flows. Unconditional promises to give are discounted using interest rates approximating fair value at the date of the gift.

Contributions and grants are conditional if the donor agreement includes both a donor-imposed barrier that must be overcome and a right of return of funds (or a release of an obligation to transfer funds). Conditional contributions are recognized as revenue once the donor-imposed barrier is overcome (typically qualifying expenses being incurred) or when right of return of the contribution to the donor no longer exists, as specified in the terms and conditions of the donor-agreement.

Contributed property and equipment is recorded at fair value at the date of donation. If donors stipulate how long the assets must be used, the contributions are recorded as support with donor restrictions. In the absence of such stipulations, contributions of property and equipment are recorded as support without donor restrictions.

(f) In-Kind Gifts

Donated materials and equipment, primarily medical supplies, are reflected in the consolidated statements of activities as contributions at their estimated fair values. Donated services are reflected as contributions if the following criteria are met: (1) the services received create or enhance nonfinancial assets or (2) the services require specialized skills, are provided by individuals possessing those skills, and would typically need to be purchased if not provided by donation. Donated services are recognized at fair value as the services are performed.

(g) Inventory

Inventory primarily consists of medication used by the Center to treat diseases that are the subject of the Center's health programs. Inventory is received as an in-kind-donation and is valued using the first in, first out method at fair value at the time of the gift. Values, as determined by the donor and independent third-party pricing information, are utilized in management's fair value estimate.

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

(h) Investments

Investments in the pooled investment fund (the Fund) (note 5) are stated at fair value as determined by the manager, Emory University. Emory University's pooled investments in securities and listed funds are valued using quoted prices in active markets, if available; otherwise, if the market is inactive, fair value is determined by Emory University in accordance with its valuation policy.

Investments in alternative investment fund structures held in the Fund are valued by Emory University using the net asset value (NAV) per share of the investment (or its equivalent), as a practical expedient, if (a) the underlying investment manager's calculation of NAV is fair value based, and (b) Emory University does not currently have plans to sell the investment for an amount different from NAV.

All other investments are stated at fair value based on quoted market prices. Investment return, including net realized and unrealized gains or losses, is recognized when earned and reported in the consolidated statement of activities.

The values of the investments in the pooled endowment fund determined by Emory University are evaluated by management of the Center who has concluded that such values are reasonable estimates of fair value at August 31, 2022 and 2021.

Investments are exposed to several risks, such as interest rate, currency, market, and credit risks. Due to the level of risk associated with certain investments, it is reasonably possible that changes in the values of investments will occur in the near term and that such changes could materially affect the amounts reported in the Center's consolidated financial statements.

The Fund may hold investments denominated in currencies other than the U.S. dollar. Thus, there is exposure to currency risk because the value of the investments denominated in other currencies may fluctuate due to changes in currency exchange rates. This can have an effect on the reported value of these assets.

The Fund's investment portfolio is subject to interest rate and credit risks for certain securities whose valuation would be impacted by changes in interest rates. The portfolio is also subject to the risk that the issuer of a debt security may be unable to pay interest or repay principal when it is due.

The value of securities held by the Fund may decline in response to certain economic events. Such events impacting valuation may include (but are not limited to) economic changes; market fluctuations; regulatory changes; global and political instability; and currency, interest rate, and commodity price fluctuations.

(i) Property, Plant, and Equipment

Property, plant, and equipment are stated at cost at the date of acquisition or at fair value at the date of donation, in the case of gifts. Depreciation is provided over the estimated useful lives of the respective assets on a straight-line basis.

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

(j) Artwork

The Center has capitalized works of art and collectibles received since its inception at the estimated fair value at the date of acquisition. Works of art with service potential that diminishes very slowly over time, to the extent that its estimated useful is extraordinarily long, are not subject to depreciation.

(k) Functional Allocation of Expenses

The costs of providing the Center's various programs and supporting services have been summarized on a functional basis in the accompanying consolidated statements of activities and functional expenses. Accordingly, certain costs have been allocated among the programs and supporting services benefited. Intervention expenses included within the Center's health program service comprise the distribution of donated medications, primarily Mectizan and Zithromax, as well as filter cloth distribution, epidemiological surveys, and health education training and material. Expenses attributable to more than one functional expense category and the basis for allocation are as follows:

Expense	Allocation basis
Depreciation	Square footage
IT department	Estimates of time and costs of specific technology utilized

(I) Federal and Other Government Grants

The Center receives funding under grants and agreements from US and other government agencies. These funds are generally considered nonreciprocal transactions and are subject to donor conditions and restrictions which are typically met by incurring qualifying expenses for a program. The Center is entitled to the funds once the conditions have been met.

For the year ended August 31, 2022, the Center received 450,000 GBP (\$583,651) from the United Kingdom Foreign Commonwealth & Development Office (FCDO), the agency formed by the September 2020 merger of the Department for International Development (DFID) and the Foreign Commonwealth Office (FCO), in support of the Center's Citizen Observer Engagement and Advocacy project in the DRC. For the year ended August 31, 2021, the Center received 1,725,244 GBP (\$2,338,123) from the UK FCDO in support of the Center's Guinea Worm Eradication Program.

For the years ended August 31, 2022 and 2021, Irish Aid contributed 200,000 Euros (\$225,464) and 200,000 Euros (\$242,376), respectively, to the Center to support Advancing Women's Right of Access to Information in Liberia.

For the year ended August 31, 2021, the Center received 87,764 Euros (\$103,414) from Irish Aid to support the Monitoring Digital Threats on Social Media in Liberia Initiative. Irish Aid also contributed 198,304 Euros (\$239,726) to the Center for the year ended August 31, 2021 to support Expanding Advancement of the Right of Access to Information for Women in Liberia.

For the years ended August 31, 2022 and 2021, the Swiss Confederation contributed \$121,918 and \$73,975, respectively, to support Civil Society Organization engagement in inclusive and credible elections in Tunisia. For the years ended August 31, 2022 and 2021, the Swiss Confederation also

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

contributed \$200,000 and \$150,000, respectively, to support Monitoring Digital Threats on Social Media in Myanmar.

(m) Tax Status

The Center and CCCI have received determination letters from the Internal Revenue Service (IRS) dated December 16, 1991 and March 22, 2007, respectively, each indicating recognition as an organization described in Section 501(c)(3) of the Internal Revenue Code (the Code) whereby only unrelated business income, as defined by Section 512(a) of the Code, is subject to federal income tax.

The Center applies Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 740, *Income Taxes* (ASC 740), which addresses the accounting for uncertainty in income tax positions. It also provides guidance on when tax positions are recognized in an entity's financial statements and how the values of these positions are determined. There is currently no impact on the consolidated financial statements as a result of ASC 740.

(n) Use of Estimates

The preparation of the consolidated financial statements requires management to make a number of estimates and assumptions relating to the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates and assumptions include the fair value of inventory; fair values of investments without readily determinable fair value; and obligations under split-interest agreements. Actual results could differ from those estimates.

(o) Recently Issued Accounting Standards

In February 2016, the FASB issued ASU No. 2016-02, *Leases* (Topic 842) (ASU 2016-02). ASU 2016-02 requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under ASC Topic 840, *Leases*. The accounting applied by a lessor under ASU 2016-02 is largely unchanged from that applied under ASC Topic 840. In June 2020, the FASB issued ASU No. 2020-05, *Revenue from Contracts with Customers (Topic 606) and Leases (Topic 842): Effective Dates for Certain Entities*, which delayed the effective date for this standard to fiscal years beginning after December 15, 2021. The Center plans to adopt ASU 2016-02 during the fiscal year ending August 31, 2023. The Center has not yet determined the impact of the new standard on its current policies but does not expect the adoption to have a material impact on the consolidated financial statements.

In March 2019, the FASB issued ASU No. 2019-03, *Not-For-Profit Entities (Topic 958) – Updating the Definition of Collections* (ASU 2019-03). The amendments in ASU 2019-03 modify the definition of the term *collections* and require that a collection holding entity disclose its policy for the use of proceeds from when collection items are deaccessioned (i.e., removed from a collection). If a collection holding entity has a policy that allows proceeds from deaccessioned collection items to be used for direct care, the ASU requires that the collection holding entity disclose its definition of direct care. The ASU is effective for annual financial statements issued for fiscal years beginning after December 15, 2019. The Center's implementation of the provisions of ASU 2019-03 during 2021 did not have a material impact on the Center's consolidated financial statements.

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

The FASB issued ASU 2020-07 *Not-For-Profit Entities (Topic 958)* on *Presentation and Disclosures by Not-For-Profit Entities for Contributed Nonfinancial Assets*, which requires organizations to present contributed nonfinancial assets as a separate line item in the statement of activities, apart from cash and other financial assets, and disaggregate into different categories of the nonfinancial assets. For each category, the qualitative information is required, and whether the contributed nonfinancial asset was monetized or utilized during the reporting period. For utilized assets the description of programs and other activities and donor imposed restrictions on the use of assets need to be disclosed. The policy about monetizing rather than utilizing nonfinancial assets, valuation techniques and principal markets used to arrive at a fair value measure at initial recognition also need to be disclosed. The term nonfinancial assets includes fixed assets (land, building, equipment) or utilities, materials, supplies, intangible assets, services and unconditional promises of these assets. The update should be applied on retrospective basis and is effective for the Center's fiscal year ended August 31, 2022. The Center's accompanying 2022 and 2021 consolidated financial statements and footnotes include the presentation and disclosure elements required by the ASU.

(p) COVID-19

During 2020, a novel strain of coronavirus (COVID-19) surfaced, the subsequent spread of which around the world and in the U.S. has caused significant volatility in the global financial markets, including those in the U.S. There is continued uncertainty as to the breadth and duration of this pandemic and the resultant market disruption. Mandates from state and local authorities have required periodic temporary closure and/or limited operations of certain schools, businesses and other facilities and organizations. While such closures and limitations on movement, both globally and in the U.S., have largely been lifted, the potential continued spread of COVID-19 and its impact on social interaction, economic activity and financial markets may adversely affect the Center's operations and financial position.

(3) Contributions Receivable

Contributions receivable consist of the following at August 31, 2022 and 2021:

	 2022	2021
With donor restrictions:		
Endowment	\$ 199,323	199,323
Health	 30,840	88,196
	\$ 230,163	287,519

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

The anticipated receipts of these receivables are as follows at August 31, 2022 and 2021:

	 2022	2021
Less than one year	\$ 230,163	287,519
One to five years	—	_
More than five years	_	_
Less unamortized discount		
	\$ 230,163	287,519

Contributions to be received after one year are discounted at an appropriate discount rate commensurate with the risks involved. Amortization of discounts is recorded as additional contribution revenue in accordance with donor-imposed restrictions on the contributions. In the opinion of the Center's management, all contributions receivable recorded at August 31, 2022 and 2021 are deemed fully collectible.

(4) Inventory

Inventory was comprised of Zithromax medication in the amount of \$4,387,783 and \$761,043 as of August 31, 2022 and 2021, respectively.

(5) Investments

The Center invests the majority of its investments in a pooled investment fund managed and held in trust by Emory University. The Center's investments also include assets invested for its charitable gift annuities and charitable remainder trusts. These investments are presented in the accompanying consolidated statements of financial position at their fair values.

	Fair value		
	2022	2021	
Pooled investments held at Emory University	\$ 1,047,539,542	1,164,791,763	
Cash and cash equivalents	393,138	244,016	
Fixed-income securities:			
Domestic mutual funds	3,741,181	4,445,017	
Equities:			
Domestic stocks	7,109,229	9,038,108	
Domestic mutual funds	90,463	110,425	
	\$ 1,058,873,553	1,178,629,329	

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

As of August 31, 2022, and 2021, respectively, the Center's investment in the pooled investment fund totaled \$1,047,539,542 and \$1,164,791,763, representing approximately 10.7% and 10.9% of the pool at each of these dates. The composition of total pooled investments held at Emory University is as follows (in thousands):

	 2022	2021
Short-term investments and cash equivalents	\$ 388,330	657,046
Public equity	3,538,101	4,542,068
Absolute return/fixed income	1,181,574	942,591
Private equity/venture capital	3,726,232	3,723,724
Real assets	949,996	826,654
Derivative instruments	 11,695	42,045
	\$ 9,795,928	10,734,128

Based on Emory University's investment policy statement, investments classified as public equity include global equity securities and commingled funds – equity, as well as alternative investments pursuing such strategies. Absolute return/fixed income investments are comprised of fixed-income securities and commingled funds – fixed income, along with alternative investments pursuing similar credit or opportunistic strategies. Private equity/venture capital includes investments in the private markets, as well as investments in private securities. Real assets include those investments in natural resources and real estate partnerships.

Emory University is subject to limitations and restrictions on its ability to redeem or sell certain of the investments included in its pooled investment fund. Such restrictions vary by investment type and range from required notice periods (generally 30 to 180 days after initial lockup periods) to specified terms at inception (generally 10 years).

The Center and Emory University entered into a Memorandum of Understanding (MOU) during September 2020 which sets forth mutual expectations regarding the management by Emory University of the Center's assets held in trust in the pooled investment fund. The MOU provides that the Center is permitted partial withdrawals of up to 10% per year (inclusive of regular spending payouts), with 30 days' written notice prior to a calendar quarter or fiscal year end. A full withdrawal request by the Center requires at least one year's written notice and is subject to a multiyear distribution schedule in line with the duration of the long-term investment portfolio, as agreed upon by both the Center and Emory University.

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

(6) Property, Plant, and Equipment

The components of property, plant, and equipment at August 31, 2022 and 2021 are as follows:

	_	2022	2021	Estimated useful lives
Land	\$	636,732	636,732	N/A
Buildings		17,580,412	17,580,412	30 years
Building improvements		3,123,015	2,716,234	15 years
Grounds and land improvements		198,243	192,884	10 years
Furniture and fixtures		1,233,613	1,061,522	10 years
Office equipment		741,364	271,457	5 years
Computer equipment	_	453,290	311,507	3 years
		23,966,669	22,770,748	
Less accumulated depreciation	_	(19,043,389)	(18,303,039)	
	\$_	4,923,280	4,467,709	

Depreciation expense totaled \$755,972 and \$666,632 during 2022 and 2021, respectively.

(7) Split-Interest Agreements

The Center is a beneficiary under several types of split-interest agreements, primarily charitable gift annuities. Under these agreements, the Center acts as trustee of assets received from donors and remits to the donor or other designee a fixed amount for a specified period of time, normally until the death of the donor or other designee. Assets related to charitable gift annuities are recorded at their fair values when received, and an annuity payment liability is recognized at the present value of future cash flows expected to be paid to the donor or other designee. At the time of the gift, the Center recognizes contribution revenue for the remainder interest in an amount equal to the difference between the fair value of the assets received and the annuity liability. Discount rates and actuarial assumptions used to determine the annuity liability are typically based on factors, such as applicable federal interest rates and life income beneficiary life expectancies, as determined by mortality tables published by the IRS. The changes in the value of these agreements are included in operating contributions and grants in the accompanying consolidated statements of activities.

Certain states have restrictions on investment allocations. Management of the Center believes it has complied with any known restrictions in states in which it has received charitable gifts subject to such restrictions.

The fair value of the assets related to split-interest agreements is included in investments in the accompanying consolidated statements of financial position and totaled \$11,334,011 and \$13,837,566 at August 31, 2022 and 2021, respectively. The annuity liability related to these agreements is \$6,204,467 and \$5,624,221 at August 31, 2022 and 2021, respectively. The net contribution revenue (loss) reported for split interest agreements as a component of contributions and grants revenue and support totaled (\$3,083,801) and \$2,510,089 for the years ended August 31, 2022 and 2021, respectively.

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

(8) Leases

The Center leases space to various entities under noncancelable operating leases with various terms. The Center leases to CCEU approximately 20% of the Center's space under a lease for a term of 99 years, with a rental payment of \$1 per year. A business agreement with the Center's caterer has no annual rent; rather, the Center receives 5% to 10% of the tenant's gross revenue, as defined in such agreement. Rental income from these leases is included in facilities use income in the accompanying consolidated statements of activities.

(9) In-Kind Gifts

The components of in-kind gifts, donated goods, and services for the years ended August 31, 2022 and 2021 are as follows:

	-	2022	2021
Health:			
Medication	\$	193,380,832	203,860,578
Other	_	295,328	474,721
	-	193,676,160	204,335,299
Peace:			
Other	-		115,000
	\$	193,676,160	204,450,299

Donations of medication were received primarily from two pharmaceutical companies for the years ended August 31, 2022 and 2021. These donations are subject to donor imposed restrictions as to location of distribution and were used in the Center's River Blindness and Trachoma programs in sub-Saharan Africa. Such donations are recorded at estimated fair value at the date of the gift. Estimates of fair value are based primarily on analyzing observable market data associated with branded, wholesale and generic pricing; geographic factors considering the U.S. as the most advantageous market; and fair value indicators provided by donors, if any.

All gifts in-kind are utilized in the year of receipt with the exception relating to the balance of medical inventory disclosed in footnote 4.

(10) Fair Value of Financial Instruments

The Center's estimates of fair value for financial assets and liabilities are based on the framework established in ASC Topic 820, *Fair Value Measurement*. This framework is based on the inputs used in valuations and gives the highest priority to quoted prices in active markets and requires observable inputs to be used in the valuations when available. The disclosure of fair value estimates in the hierarchy described below is based on whether the significant inputs into the valuation are observable. In determining the level of the hierarchy in which the estimate is disclosed, the highest priority is given to unadjusted

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

quoted prices in active markets and the lowest priority to unobservable inputs that reflect the Center's significant market assumptions. The three levels of the fair value hierarchy are as follows:

Level 1 – Valuations based on unadjusted quoted market prices for identical assets or liabilities in active markets.

Level 2 – Valuations based on pricing inputs that are other than quoted prices in active markets, which are either directly or indirectly observable; examples include quoted prices in active markets of the underlying assets, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in an inactive market, or valuations based on models where significant inputs are observable or can be corroborated by observable market data.

Level 3 – Valuations are derived from other valuation methodologies, including pricing models, discounted cash flow models, and similar techniques. Level 3 valuations incorporate certain assumptions and projections that are not observable in the market and require significant professional judgment in determining the fair value assigned to such assets or liabilities.

The fair value hierarchy requires the use of observable market data when available. As required by ASC Topic 820, assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurements.

Contributions receivable for current year gifts are initially measured at fair value in the year the receivable is recorded based on the present value of future cash flows discounted at a rate commensurate with risks involved, which is an application of the income approach. At August 31, 2022 and 2021 there were no current year gifts included in contributions receivable.

The carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, and deferred revenue approximates fair value because of the relative terms and short maturity of these financial instruments. The carrying value of annuity obligations approximates fair value and is based on the present value of the estimated future cash flows.

NAV was used as a practical expedient estimate of fair value relative to the Center's interest in the Emory University pooled endowment fund. NAV, in many instances, may not equal fair value that would be determined pursuant to ASC Topic 820. There are no redemption restrictions on the Center with respect to its pooled investments held at Emory University. Investments that are valued using the practical expedient, as described above, are labeled as NAV and are not categorized within the fair value hierarchy. The Center does not hold any investments that would be categorized as Level 3 investments as of August 31, 2022 and 2021, respectively.

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

The following table summarizes the valuation of the Center's financial instruments, which are recorded at fair value by the ASC Topic 820 fair value hierarchy levels as of August 31, 2022:

	_	Level 1	NAV	Total
Assets:				
Cash and cash equivalents	\$	75,845,672	—	75,845,672
Fixed-income securities:				
Domestic mutual funds		3,741,181	_	3,741,181
Equities:				
Domestic stocks		7,109,229	_	7,109,229
Domestic mutual funds		90,463	—	90,463
Interest in Emory University pooled				
endowment fund	_		1,047,539,542	1,047,539,542
Total	\$_	86,786,545	1,047,539,542	1,134,326,087

The following table summarizes the valuation of the Center's financial instruments, which are recorded at fair value by the ASC Topic 820 fair value hierarchy levels as of August 31, 2021:

		Level 1	NAV	Total
Assets:				
Cash and cash equivalents	\$	66,528,115	—	66,528,115
Fixed-income securities:				
Domestic mutual funds		4,445,017	—	4,445,017
Equities:				
Domestic stocks		9,038,108	—	9,038,108
Domestic mutual funds		110,425	—	110,425
Interest in Emory University pooled				
endowment fund			1,164,791,763	1,164,791,763
Total	\$_	80,121,665	1,164,791,763	1,244,913,428

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

(11) Net Assets

(a) Net Assets without Donor Restrictions

As of August 31, 2022 and 2021, net assets without donor restrictions are as follows:

	_	2022	2021
Undesignated	\$	46,466,338	34,166,313
Board-designated for:			
Endowment investment, subject to spending policy			
and appropriation		377,024,986	420,522,974
	\$_	423,491,324	454,689,287

Net assets without donor restrictions include funds internally designated for endowment investment and program funding. These amounts are classified as net assets without donor restrictions due to the lack of explicit donor stipulations that restrict their use. Unrealized gains or losses on internally designated endowment funds are classified as changes in net assets without restrictions.

(b) Net Assets with Donor Restrictions

As of August 31, 2022 and 2021, net assets with donor restrictions are available for the following purposes:

	_	2022	2021
Donor-restricted for specified purposes:			
Health	\$	7,289,000	10,061,935
Peace		612,543	1,812,933
Cross-program	_	23,507,730	20,517,735
	_	31,409,273	32,392,603
Donor-restricted endowments subject to spending policy and appropriation, to support the following purposes:			
Health		20,496,911	22,798,610
Peace		2,917,276	3,254,261
Cross-program		2,776,147	488,144
General activities	_	652,056,068	727,213,351
	_	678,246,402	753,754,366
	\$_	709,655,675	786,146,969

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

Of the donor-restricted endowment net assets noted above, \$165.2 million and \$164.9 million as of August 31, 2022 and 2021, respectively, represent donor-restricted endowment corpus. The remaining \$513.0 million and \$588.8 million as of August 31, 2022 and 2021, respectively, represent appreciation and reinvested earnings related to the donor-restricted corpus but for which the Center's management and board have full discretion to use within the donor-stipulated purpose, if any, as noted above.

(12) Endowment Funds

The Center's endowment funds consist of individual donor-restricted endowment funds and funds designated by the Board to function as endowments. The net assets associated with endowment funds, including those funds designated by the Board to function as endowment, are classified and reported based on the existence or absence of donor-imposed restrictions.

(a) Interpretation of Relevant Law

The Center has interpreted the Uniform Prudent Management of Institutional Funds Act (UPMIFA), as adopted by the State of Georgia, as providing, among other things, expanded spending flexibility by allowing, subject to a standard of prudence, spending from an endowment without regard to the book value of the corpus of the fund. As a result of this interpretation, the Center classifies as net assets with donor restrictions (a) the original value of gifts donated to the endowment, (b) the original value of subsequent gifts to the endowment, and (c) accumulations to the endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund.

In accordance with UPMIFA, the Center considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds:

- The duration and preservation of the fund
- The purposes of the Center and the donor-restricted endowment fund
- General economic conditions
- The possible effect of inflation and deflation
- The expected total return from income and the appreciation of investments
- Other resources of the Center
- The investment policies of the Center.

The Center invests its endowment assets in a pooled investment fund managed by Emory University. The Board follows the investment return objectives and the spending policy, as directed and managed by Emory University's board of trustees, as set forth in more detail below.

(b) Return Objectives and Risk Parameters

The Center supports Emory University's investment and spending policies, the objective of which is to provide a predictable stream of funding to programs supported by its endowment while seeking to maintain the purchasing power of the endowment assets. Under this investment policy, as approved by Emory University's board of trustees, the endowment assets are invested within risk tolerances of Emory University to provide an expected total return in excess of spending and inflation over the long term.

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

(c) Strategies Employed for Achieving Objectives

To satisfy its long-term return objectives, the Center relies on Emory University's total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). Emory University employs a diversified asset allocation strategy across public equity, absolute return/fixed income, private equity/venture capital, real assets, and derivative instruments to achieve its long-term return objectives within a prudent risk framework.

(d) Spending Policy and How the Investment Objectives Relate to Spending Policy

The Center follows Emory University's total return endowment spending policy that establishes the maximum amount of endowment investment return available to support current operating and capital needs. The Center considered the expected return on its endowment, including the effect of inflation in setting the annual appropriation amount. Accordingly, the Center expects the current spending policy to allow its endowment to maintain its purchasing power if projected growth rates are achieved. Additional real growth will be provided by new gifts and any excess investment return.

Endowment funds consist of the following as of August 31, 2022:

	_	Without donor restrictions	With donor restrictions	Total
Donor-restricted endowment funds Board-designated endowment funds	\$		678,246,402	678,246,402 377,024,986
Total funds	\$_	377,024,986	678,246,402	1,055,271,388

Endowment funds consist of the following as of August 31, 2021:

	_	Without donor restrictions	With donor restrictions	Total
Donor-restricted endowment funds Board-designated endowment funds	\$	 420,522,974	753,754,366	753,754,366 420,522,974
Total funds	\$_	420,522,974	753,754,366	1,174,277,340

There were no underwater endowment funds during the years ended August 31, 2022 or 2021.

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

Changes in endowment funds for the year ended August 31, 2022, are as follows:

	-	Without donor restrictions	With donor restrictions	Total
Endowment funds, August 31, 2021 Contributions	\$	420,522,974 689,203	753,754,366 309,185	1,174,277,340 998,388
Investment return: Endowment fund earnings Appreciation of endowment		13,180,421	23,230,237	36,410,658
investments, net	-	(44,187,191)	(75,817,149)	(120,004,340)
Total investment return		(31,006,770)	(52,586,912)	(83,593,682)
Appropriation of endowment assets for expenditure	-	(13,180,421)	(23,230,237)	(36,410,658)
Endowment funds, August 31, 2022	\$	377,024,986	678,246,402	1,055,271,388

Changes in endowment funds for the year ended August 31, 2021, are as follows:

	-	Without donor restrictions	With donor restrictions	Total
Endowment funds, August 31, 2020 Contributions	\$	312,079,961 757,495	560,997,160 32,593	873,077,121 790,088
Investment return: Endowment fund earnings Appreciation of endowment		12,698,652	22,378,343	35,076,995
investments, net	_	107,685,518	193,112,940	300,798,458
Total investment return		120,384,170	215,491,283	335,875,453
Appropriation of endowment assets for expenditure	_	(12,698,652)	(22,766,670)	(35,465,322)
Endowment funds, August 31, 2021	\$_	420,522,974	753,754,366	1,174,277,340

Notes to Consolidated Financial Statements

August 31, 2022 and 2021

(13) Liquidity and Availability of Financial Assets

The Center's financial assets available for general expenditure within one year of August 31, 2022 and 2021 are as follows:

	2022	2021
Total assets	\$ 1,155,395,889	1,259,295,922
Less:		
Net assets with donor restrictions for		
specified purpose, net of inventory	(27,021,490)	(31,631,560)
Donor-restricted and board-designated		
endowment funds	(1,055,271,388)	(1,174,277,340)
Inventory	(4,387,783)	(761,043)
Property, plant, and equipment	(4,923,280)	(4,467,709)
Artwork	(2,435,365)	(2,435,365)
Other assets	(33,286)	(214,191)
Deferred revenue	(6,111,603)	(4,790,884)
Annuity obligations	(6,204,467)	(5,624,221)
	\$ 49,007,227	35,093,609

The primary sources of liquidity for the Center are cash accounts at headquarters and in the field. The Center structures its financial assets to be available as its general expenditures, liabilities, and other obligations come due. In the event of unanticipated liquidity needs, the Center's board of trustees may turn to the portion of the Center's endowment classified as without donor restrictions for consideration.

(14) Related–Party Transactions

Emory University provides certain administrative functions to the Center, including, but not limited to, payroll administration, investment management, information technology, and legal services. The Center paid Emory University \$690,156 during both the years ended August 31, 2022 and 2021, respectively, for the provision of these services.

Emory University made unrestricted contributions to the Center of \$779,989 and \$753,904, respectively, for the years ended August 31, 2022 and 2021. In addition, CCEU made unrestricted contributions to CCI, primarily related to endowment earnings at CCEU, of \$484,791 and \$468,592 for the years ended August 31, 2022 and 2021, respectively.

(15) The Carter Center Collaborative, Inc. (CCCI)

CCCI received donations of in-kind goods for the benefit of the Center totaling \$193,380,832 and \$203,860,578 for the years ended August 31, 2022 and 2021, respectively, that are included in the accompanying consolidated statements of activities. Expenses totaling \$189,901,562 and \$205,348,901 related to the use or grant of these donations are also included in the accompanying consolidated statements of activities 31, 2022 and 2021, respectively. Inventory related to these goods for CCCI totaled \$4,387,783 and \$761,043 as of August 31, 2022 and 2021, respectively, and is included in the accompanying consolidated statements of financial position.

Notes to Consolidated Financial Statements August 31, 2022 and 2021

(16) Commitments and Contingencies

Federal Financial Assistance

Federally funded programs are routinely subject to special audits that could result in claims against the resources of the Center. Management does not believe that there will be any claims arising from such audits that could have a material adverse effect on the financial position of the Center.

(17) Subsequent Events

The Center has evaluated subsequent events from the consolidated statement of financial position date through May 5, 2023, the date on which the consolidated financial statements were available to be issued and determined that there are none requiring adjustment or disclosure in the accompanying consolidated financial statements and related footnotes.